Amundi
RPRX icon

Amundi’s Royalty Pharma RPRX Stock Holding History

Amundi’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209M Buy
3,723,864
+635,091
+21% +$33.1M 0.05% 301
2026
Q1 		$148M Buy
3,088,773
+409,394
+15% +$17.9M 0.04% 360
2025
Q4 		$104M Buy
2,679,379
+609,394
+29% +$23.2M 0.03% 481
2025
Q3 		$74.8M Sell
2,069,985
-727,486
-26% -$26.3M 0.02% 470
2025
Q2 		$101M Buy
2,797,471
+1,560,093
+126% +$51.7M 0.03% 412
2025
Q1 		$39.3M Sell
1,237,378
-1,316,620
-52% -$41.7M 0.01% 582
2024
Q4 		$66.9M Sell
2,553,998
-1,137,257
-31% -$30.2M 0.02% 503
2024
Q3 		$101M Buy
3,691,255
+1,627,093
+79% +$45.1M 0.04% 398
2024
Q2 		$53.5M Sell
2,064,162
-144,293
-7% -$4M 0.02% 506
2024
Q1 		$61.6M Sell
2,208,455
-1,484,441
-40% -$43.8M 0.03% 473
2023
Q4 		$105M Buy
3,692,896
+2,080,841
+129% +$57.2M 0.05% 376
2023
Q3 		$44.9M Buy
1,612,055
+239,735
+17% +$7.12M 0.02% 531
2023
Q2 		$42.1M Buy
1,372,320
+339,635
+33% +$11.5M 0.02% 546
2023
Q1 		$37.5M Buy
1,032,685
+176,317
+21% +$6.54M 0.02% 571
2022
Q4 		$33.7M Buy
856,368
+26,762
+3% +$1.12M 0.02% 585
2022
Q3 		$34.6M Sell
829,606
-106,960
-11% -$4.57M 0.02% 578
2022
Q2 		$40.4M Buy
936,566
+636,589
+212% +$26.1M 0.03% 485
2022
Q1 		$12.2M Buy
299,977
+100,254
+50% +$3.94M 0.01% 762
2021
Q4 		$8.03M Sell
199,723
-1,193,558
-86% -$46.4M 0.01% 898
2021
Q3 		$50.4M Sell
1,393,281
-1,434,984
-51% -$55.8M 0.04% 444
2021
Q2 		$116M Buy
+2,828,265
New +$120M 0.08% 258

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amundi's RPRX Position: Q2 2026 in Review

Amundi increased its Royalty Pharma (RPRX) stake by 21% in Q2 2026, buying an estimated $33.1M and bringing the position to 3,723,864 shares worth $209M. The position accounts for 0.05% of the portfolio, ranked #301.

Amundi first reported a position in RPRX in Q2 2021 and has held it in 21 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Amundi held 3,723,864 shares of Royalty Pharma worth $209M as of Q2 2026.
  • Amundi bought 635,091 Royalty Pharma shares in Q2 2026, an estimated $33.1M.
  • Royalty Pharma made up 0.05% of Amundi's portfolio in Q2 2026, its #301 holding.
  • Amundi first reported a position in Royalty Pharma in Q2 2021 and has held it in 21 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.